New peptide drug PQ203 enters human trials for Hard-to-Treat cancers
Disease control
Recruiting now
This early-stage trial is testing a new drug called PQ203 in about 80 adults with advanced solid tumors, including triple-negative breast cancer, that have not responded to standard treatments. The drug is given as a weekly intravenous infusion. The main goals are to check safety…
Phase: PHASE1 • Sponsor: ProteinQure Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC